Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Beats Revenue Estimates

Financial Performance - Syndax Pharmaceuticals reported a quarterly loss of $0.83 per share, which is better than the Zacks Consensus Estimate of a loss of $1, representing an earnings surprise of +17.00% [1] - The company posted revenues of $37.96 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 30.74%, compared to revenues of $3.5 million in the same quarter last year [2] - Over the last four quarters, Syndax has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] Stock Performance - Syndax shares have declined approximately 24.5% since the beginning of the year, while the S&P 500 has gained 6.1% [3] - The current Zacks Rank for Syndax is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.81 on revenues of $36.49 million, and for the current fiscal year, it is -$3.64 on revenues of $136.56 million [7] - The trend of estimate revisions for Syndax was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - Syndax operates within the Medical - Biomedical and Genetics industry, which is currently ranked in the bottom 43% of over 250 Zacks industries [8] - Empirical research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1 [8]